stockrowRecursion Pharmaceuticals, Inc.
RXRX Healthcare Biotechnology
Recursion Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.7 million, up 26.9% from fiscal 2024.
- Revenue
- +258.5%
- EPS
- +39.1%
- Free cash flow
- +33.8%
- Total debt
- −99.2%
Quarter to September 2026, against a year earlier
Follow RXRX
Alert me
Recursion Pharmaceuticals, Inc. (RXRX) Free cash flow
Recursion Pharmaceuticals, Inc.'s free cash flow for fiscal 2025 was −$380.4M, compared with −$376.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$314.5M. Over the past ten years it has ranged from −$380.4M (fiscal 2025) to −$45.4M (fiscal 2020) — the current reading is the lowest in ten years. Free cash flow has fallen for 4 consecutive fiscal years. Recursion Pharmaceuticals, Inc. ranks 570th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$380.4M | — |
| FY2024 | −$376.2M | — |
| FY2023 | −$300.3M | — |
| FY2022 | −$120.9M | — |
| FY2022 | −$83.5M | — |
| FY2021 | −$198.4M | — |
| FY2021 | −$158.6M | — |
| FY2020 | −$52.1M | — |
| FY2020 | −$45.4M | — |
| FY2019 | −$61.0M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | −$77.8M | — |
| Jun 2026 | −$107.9M | — |
| Mar 2026 | −$81.4M | — |
| Dec 2025 | −$47.3M | — |
| 24 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| ADMA ADMA Biologics Inc compare | $140.5M |
| VCEL Vericel Corporation compare | $57.9M |
| PVLA Palvella Therapeutics, Inc. compare | −$36.5M |
| MBX MBX Biosciences, Inc. compare | −$85.2M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$150.9M |
| PHVS Pharvaris N.V. compare | −$178.1M |
| CLDX Celldex Therapeutics, Inc. compare | −$242.1M |
| RXRX Recursion Pharmaceuticals, Inc. | −$314.5M |
| BHVN Biohaven Ltd. compare | −$473.2M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on RXRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement